Vilon vs Chonluten: what each one actually has going for it

I get asked some version of this question constantly in the Khavinson-peptide corner of my inbox: if Vilon and Chonluten are both short Russian bioregulator peptides, why does one show up in actual patient studies and the other barely shows up at all. Short answer: Vilon has a real human research trail behind it and Chonluten does not, and that gap is the whole story of why these two peptides, despite sharing a family tree, are not interchangeable.

Both come out of the Khavinson short-peptide program, the Russian school of dipeptide and tripeptide "bioregulators" built on the idea that short amino acid chains can nudge gene expression in a tissue-specific way. Vilon is the immune and geroprotective member. Chonluten is aimed at lung epithelium and the mucosal barrier. Same family, different jobs, and very different amounts of proof behind those jobs.

Evidence quality: this is where the comparison actually gets decided

Vilon has a genuine cohort record. Kuznik's group ran it in elderly diabetics and saw improved coagulation and immune markers along with reduced insulin requirements, and in a separate cohort it reduced DIC syndrome in people with type-1 diabetes. There's also a case series in elderly stage-III colorectal cancer patients showing improved survival and fewer complications. On top of the human data, there's a solid in-vitro line: Vilon increased SIRT1 and lowered PARP1/PARP2 expression in aging human mesenchymal stem cells, and separately drove selective heterochromatin decondensation in elderly lymphocytes, which is the mechanistic story for how a two-amino-acid peptide might be doing anything at all at the chromatin level.

Chonluten has one citation, period. It's an in-vitro study on the THP-1 monocyte and macrophage cell line, where Chonluten modulated proliferative activity and inflammatory pathways like TNF and IL-6. No human trials. No animal studies. Nothing else in the published record specific to this peptide. It is not that Chonluten has been tested and failed. It's that Chonluten has barely been tested.

I try to stay evidence-based with peptides, and when the gap between two family members is this stark, I think it needs to be said plainly rather than softened into "both have promising research." Vilon has research. Chonluten has a research direction someone sketched out once in a dish.

Side-effect load: both are quiet, for the same reason

Neither peptide has a documented adverse event pattern beyond the family-wide baseline: occasional injection-site irritation and the odd mild headache early in a cycle. That mild profile is genuinely reassuring, but I don't think it should be read as evidence of safety so much as evidence of how little either compound has been studied. A peptide with three human cohort studies and a peptide with zero human studies can both report "no serious adverse events" and mean very different things by it.

The real risk for both isn't the molecule anyway, it's the supply chain. Khavinson-family peptides are the most counterfeited category in the peptide space, and Chonluten's thin published record makes it an even easier target for mislabeling than Vilon, since there's less of a documented profile to compare a vial against. If you're sourcing either one, a third-party certificate of analysis matters more here than almost anywhere else in this catalog.

Cost and who each one actually suits

Cost-wise, the two run close, since both are short peptides dosed at similar community protocols: subcutaneous, roughly 100 to 200 mcg per day, run in a 10 to 20 day cycle, repeated 2 to 3 times a year. There's no Western-validated dosing for either one. Everything above is the Russian-school and peptide-community convergence, not a clinically established protocol.

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

So who does each one suit. If your interest is immune function or general geroprotective use in an older population, and you want the Khavinson peptide with the most human data to point to, Vilon is the clear pick. I'd also point you toward thymosin alpha-1 if what you actually want is a Western-evidenced thymic immune peptide with a deeper trial record and easier verified sourcing, since Vilon and its siblings are more the historical Russian-school context around that same target than the best-evidenced option in it.

If your interest is specifically respiratory or mucosal, Chonluten is the only Khavinson peptide aimed at that tissue, so it fills a niche nothing else in this comparison does. That's worth being honest about even though the evidence is thin: nobody has run this in humans, we have one in-vitro study on inflammatory cytokines in a monocyte cell line, and that's the entire case for it right now. I see this a lot with clients who want to try a peptide because the theory is interesting rather than because the data is there yet, and Chonluten is squarely in that category.

For dosing frameworks, sourcing questions, and how to think about running a peptide with thin human data responsibly, my piece on whether peptides are actually dangerous walks through the same evidence-tier thinking I'm using here.

The pair does different jobs on paper, immune and geroprotective versus lung and mucosal, but only one of them has earned that job description with real trial data. Vilon has proof. Chonluten has a hypothesis.